Literature DB >> 10519911

Pharmaceutical VIP: prospects and problems.

I Gozes1, M Fridkinb, J M Hill, D E Brenneman.   

Abstract

Recently, multiple receptors for vasoactive intestinal peptide (VIP) have been molecularly cloned and our understanding of VIP chemistry and mechanisms of action has been broadened. The following review outlines the physiological effects of the hormone from growth regulation, reproduction, bronchodilation, vasodilation and immune interactions to neurotrophism. VIP-based drug design and non-invasive innovative delivery modes are discussed with emphasis on tumor diagnosis and treatment, impotence treatment and neuroprotection.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10519911

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN： 0929-8673            Impact factor:   4.530


  16 in total

1.  (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.

Authors:  Terry W Moody; Robert T Jensen; Mati Fridkin; Illana Gozes
Journal:  J Mol Neurosci       Date:  2002 Feb-Apr       Impact factor: 3.444

2.  NAP accelerates the performance of normal rats in the water maze.

Authors:  Illana Gozes; Roy Alcalay; Eliezer Giladi; Albert Pinhasov; Sharon Furman; Douglas E Brenneman
Journal:  J Mol Neurosci       Date:  2002 Aug-Oct       Impact factor: 3.444

3.  VIP, from gene to behavior and back: summarizing my 25 years of research.

Authors:  Illana Gozes
Journal:  J Mol Neurosci       Date:  2008-07-08       Impact factor: 3.444

4.  Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.

Authors:  Jolanta B Zawilska; Agnieszka Dejda; Pawel Niewiadomski; Illana Gozes; Jerzy Z Nowak
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

5.  Antiproliferative effects of PACAP and VIP in serum-starved glioma cells.

Authors:  Agata Grazia D'Amico; Soraya Scuderi; Salvatore Saccone; Alessandro Castorina; Filippo Drago; Velia D'Agata
Journal:  J Mol Neurosci       Date:  2013-07-31       Impact factor: 3.444

6.  The vasoactive intestinal peptide (VIP) alpha-Helix up to C terminus interacts with the N-terminal ectodomain of the human VIP/Pituitary adenylate cyclase-activating peptide 1 receptor: photoaffinity, molecular modeling, and dynamics.

Authors:  Emilie Ceraudo; Samuel Murail; Yossan-Var Tan; Jean-Jacques Lacapère; Jean-Michel Neumann; Alain Couvineau; Marc Laburthe
Journal:  Mol Endocrinol       Date:  2007-09-20

7.  The N-terminal parts of VIP and antagonist PG97-269 physically interact with different regions of the human VPAC1 receptor.

Authors:  Emilie Ceraudo; Yossan-Var Tan; Pascal Nicole; Alain Couvineau; Marc Laburthe
Journal:  J Mol Neurosci       Date:  2008-07-03       Impact factor: 3.444

8.  Production and purification of large quantities of the functional N-terminal ectodomain of human VPAC1 receptor.

Authors:  Alain Couvineau; Jean-Claude Robert; Tarik Ramdani; Jean-Jacques Lacapère; Christiane Rouyer-Fessard; Marc Laburthe
Journal:  J Mol Neurosci       Date:  2008-07-01       Impact factor: 3.444

9.  Effects of PACAP and VIP on cAMP-generating system and proliferation of C6 glioma cells.

Authors:  Paulina Sokolowska; Jerzy Z Nowak
Journal:  J Mol Neurosci       Date:  2008-05-20       Impact factor: 3.444

Review 10.  Neuroprotection against neurodegenerative diseases: development of a novel hybrid neuroprotective peptide Colivelin.

Authors:  Tomohiro Chiba; Ikuo Nishimoto; Sadakazu Aiso; Masaaki Matsuoka
Journal:  Mol Neurobiol       Date:  2007-02       Impact factor: 5.590
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.